Liver manifestations in COVID-19 patients: A review article

Table 1 Liver injury in coronavirus disease 2019 patients in different trials

Ref.	Number of patients infected with COVID-19	Patients with liver injury (percentage)	Patients with preexisting liver damage (percentage)	Elevated indicators	Mortality
Chen et al[23]	99	43 (43.4)	-	43 patients had differing degrees of liver function abnormality. Prothrombin time increased by 5%, one patient had severe liver function damage (ALT: 7590 U/L, AST: 1445 U/L)	11% (day 24)
Wang et al[27]	69	42 (60.9)	1 (1)	Abnormal ALT: 33%; abnormal AST: 28%	7.5% (day 19)
Cai et al[28]	298	44 (14.8)	8 (2.7)	Abnormal ALT: 13.1%; abnormal AST: 8.4%	1% (day 55)
Zhang et al[29]	82 death cases	64 (78.0)	2 (2.4)	Abnormal ALT: 30.6%; abnormal AST: 61.1%; abnormal total bilirubin 30.6%	ALT (> 40 U/L), AST (> 40 U/L), and TBIL (> 20.5 mmol/L) increased in 30.6%, 61.1%, and 30.6% cases
Wang et al[30]	138	55 (39.9)	4 (29)	Abnormal ALT: 17.4%; abnormal AST: 22.5%	4.3% (day 33)
Li et al[31]	85	33 (38.8)	6 (7)	Abnormal ALT: 38.8%	-
Yang et al[32]	52	15 (28.9)	15 (29)	-	62% (day 28)
Fan et al[33]	148	75 (50.7)	6 (8)	Abnormal ALT: 18.2%; abnormal AST: 21.6%	0.67% (day 11)
Huang et al[24]	41	15 (36.6)	1 (2)	Abnormal AST: 37%	15% (day 17)
Guan et al[22]	67	22 (32)	Hepatitis B: 2.1%	Abnormal ALT: 21.3%; abnormal AST: 22.2%	22% (day 51)
Shi et al[34]	81	42 (53)	Hepatitis or liver cirrhosis in 9% of cases	Abnormal AST: 53%	5% (day 50)
Xu et al[35]	62	4 (12)	7 (11)	Levels of AST increased in 10 (16%) patients	0% (day 34)

COVID-19: Coronavirus disease 2019; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; TBIL: Total bilirubin.